Moderna Prices $2.6 Billion Zero‑Coupon Convertible Notes With Capped Calls

Overview

• Moderna privately priced $2.6 billion of zero‑coupon convertible senior notes due March 1, 2032 in a Rule 144A placement that can be increased by an option for more notes.
• The initial conversion rate is 4.7487 shares per $1,000 principal, equal to a conversion price of about $210.58 per share, and the company paired the notes with capped‑call hedges to limit dilution within a set range.
• The capped call starts at a strike near $392.62 and Moderna expects to spend roughly $285 million of offering proceeds on those hedges, which reduces the net capital available for R&D and commercialization.
• Moderna said net proceeds would be used for the capped calls, general corporate purposes, oncology expansion and possible debt repayment, with estimated net proceeds of about $2.56 billion rising toward $2.96 billion if the additional option is exercised.
• Investors reacted with a share pullback and analysts caution that the structure preserves cash now but creates a senior unsecured 2032 obligation that could mean dilution or cash settlement depending on future stock performance and clinical or commercial execution.